
Open access publishing of pharma-sponsored research: insights from a Scientific Publications Lead
Slávka Baróniková shares her opinions on open access publishing and suggests how this can be successfully achieved within pharma.
A central online news resource for professionals involved in the development of medical publications and involved in publication planning and medical writing.
Slávka Baróniková shares her opinions on open access publishing and suggests how this can be successfully achieved within pharma.
cOAlition S Rights Retention Strategy aims to safeguard researchers’ intellectual ownership, enabling embargo-free sharing of research in online repositories.
From 2022, journals will need to follow cOAlition S price transparency requirements to get paid. Find out more about the frameworks and potential benefits here.
Following a public consultation, updated cOAlition S guidance relaxes the criteria for transformative journals, prompting commitments from further journals.
The latest State of Open Data survey results show changing trends in researchers’ attitudes towards the use of open data.
Find out more about the requirements cOAlition S plans to set for ‘transformative journals’.
Following the revised guidance on Plan S, Bernd Pulverer questions whether cOAlition S is making the most of the opportunity to push for open science.
A new tool from MPIP provides easily accessible information on open access options for industry-funded research.
There are a number of publishing features to consider when selecting a journal. Find out how researchers are navigating the options to their best advantage.
Article processing charges are increasing, but a recent study finds that higher charges seem to attract rather than deter authors from submitting to open access journals.
ISMPP’s first white paper, ‘A multistakeholder discussion on open access and medical publishing’ is now available.
A recent article from The Chronicle of Higher Education discusses the potential benefits associated with journals that are established by funding bodies.
Feedback on the implementation guidance for Plan S highlights key themes for consideration.
Many public funders have mandated open access to their research and support Plan S. Should pharmaceutical companies follow suit?
China has pledged its support for Plan S, an initiative striving to make the results of publicly funded research freely available immediately on publication.